0001564590-22-024881.txt : 20220630 0001564590-22-024881.hdr.sgml : 20220630 20220630073516 ACCESSION NUMBER: 0001564590-22-024881 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220630 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220630 DATE AS OF CHANGE: 20220630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH SERVICES INC CENTRAL INDEX KEY: 0000352915 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 232077891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10765 FILM NUMBER: 221056531 BUSINESS ADDRESS: STREET 1: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 6107683300 MAIL ADDRESS: STREET 1: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 8-K 1 uhs-8k_20220630.htm 8-K uhs-8k_20220630.htm
false 0000352915 0000352915 2022-06-30 2022-06-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2022

 

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

1-10765

 

23-2077891

(State or other jurisdiction of

 

(Commission

 

(I.R.S. Employer

Incorporation or Organization)

 

File Number)

 

Identification No.)

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania 19406

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class B Common Stock

UHS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Information

On June 30, 2022, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

 

 

99.1

  

Universal Health Services, Inc., press release, dated June 30, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

Exhibit Index

 

Exhibit No.

  

Exhibit

 

 

99.1

  

Universal Health Services, Inc., press release, dated June 30, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Universal Health Services, Inc.

 

By:

 

/s/ Steve Filton

Name: Steve Filton

Title: Executive Vice President and

            Chief Financial Officer

Date: June 30, 2022

 

 

 

 

 EX-99.1 2 uhs-ex991_6.htm EX-99.1 uhs-ex991_6.htm

 

Exhibit 99.1

FOR IMMEDIATE RELEASE

June 30, 2022

 

CONTACT:

Steve Filton

 

Chief Financial Officer

 

610-768-3300

 

UNIVERSAL HEALTH SERVICES, INC.

PROVIDES UPDATE ON OPERATING RESULTS FOR THE SECOND QUARTER OF 2022 AND REVISES 2022 FULL YEAR EARNINGS GUIDANCE

 

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that, due to a significant shortfall in operating results experienced during April and May of 2022, as compared to the comparable periods included in our previously provided annual operating results forecast, we are revising our forecast for the year ended December 31, 2022.

Based upon our consolidated results of operations for April and May of 2022, we estimate that our adjusted net income attributable to UHS will approximate $2.05 to $2.15 per diluted share for the three-month period ended June 30, 2022. The lower than expected earnings projected for the second quarter of 2022 was due primarily to lower than expected patient volumes, revenues and income generated at our acute care hospitals. During April and May of 2022, our acute care hospitals experienced a significant decline in COVID-related patients, as compared to the first quarter of 2022. The decrease in COVID-related patient volumes during the second quarter of 2022 was not offset by an equivalent increase in non-COVID-related patients resulting in significant shortfalls in revenues and earnings as compared to our original forecasts for that period. Although the decreased patient volumes at our acute care hospitals has relieved some of the staffing shortages and related cost escalations previously experienced at those facilities, recovery from the effects of the labor pressures has been occurring at a somewhat slower pace than expected.  During April and May of 2022, patient volumes, revenues and income generated at our behavioral health care facilities were also below our expectations. However, the shortfalls from internal expectations experienced within our behavioral health segment were relatively consistent with those experienced during the first quarter of 2022.            

In the announcement of our financial results for the first quarter of 2022 (as released on April 25, 2022), we indicated that, given the continued uncertainties related to the COVID-19 pandemic, as well as the healthcare staffing shortage and its unfavorable impact on our labor costs and behavioral health patient volumes, we may make reductions to our 2022 full year operating results forecast at a future date if the unfavorable operating trends experienced during the first quarter of 2022 did not improve.  Based upon the operating trends and financial results experienced during April and May of 2022, as discussed above, along with our financial results for the first quarter of 2022, we are decreasing our guidance ranges for the year ended December 31, 2022 for each of the following: (i) net revenues; (ii) earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests (“Adjusted EBITDA, net of NCI”), and; (iii) adjusted net income attributable to UHS per diluted share (“Adjusted EPS-diluted”).

The tables below include our revised 2022 operating results forecasts for the year ended December 31, 2022, as well as our original 2022 operating results forecast which was previously disclosed on February 24, 2022.

 

 

 

 

 

 

 

 

 

Revised Forecast

 

Original Forecast

 

For the Year Ended

 

For the Year Ended

 

December 31, 2022

 

December 31, 2022

 

Low

High

 

Low

High

Net revenues

$13.235 billion

$13.371 billion

 

$13.424 billion

$13.694 billion

Adjusted EBITDA, net of NCI

$1.635 billion

$1.712 billion

 

$1.830 billion

$1.927 billion

Adjusted EPS - diluted

$9.60 per share

$10.40 per share

 

$11.90 per share

$12.90 per share

 

•

Our revised 2022 forecasted net revenues are estimated to be approximately $13.235 billion to $13.371 billion, representing decreases of 1.4% to 2.4% as compared to our original 2022 forecasted net revenues.  

 

•

Our revised 2022 forecasted Adjusted EBITDA, net of NCI, is estimated to be approximately $1.635 billion to $1.712 billion, representing decreases of 10.7% to 11.2% as compared to our original 2022 forecasted Adjusted EBITDA, net of NCI.

 

•

Our revised 2022 forecasted Adjusted EPS-diluted is estimated to be $9.60 per share to $10.40 per share, representing decreases of 19.3% as compared to our original 2022 forecasted Adjusted EPS-diluted.  

Our revised operating results forecast for the balance of 2022 assumes that staffing vacancies and the corresponding premium pay expenditures will continue to sequentially decline in the second half of the year and that non-COVID patient volumes will incrementally improve, although both at a slower pace than our original forecast anticipated. We believe these assumptions will be bolstered by our continuing recruitment and retention initiatives, by changes to our historical patient care models, by other cost cutting measures and by aggressive contractual negotiations and renegotiations with our managed care payers.  In addition, during the second half of 2022, we also expect sequential improvement in startup losses incurred during the first half of 2022 at newly constructed and recently opened acute care and behavioral health hospitals.  Included in our revised operating results forecast for the year ended December 31, 2022, as compared to the original forecast, is a $28 million increase in depreciation and amortization expense which includes additional depreciation expense expected to be incurred at one of our acute care hospitals located in California on which a major renovation project has commenced. The renovation plans for this facility, which includes construction of a new seven-story tower, requires demolition of a significant portion of the existing building over the next few years.  

Adjusted EPS-diluted and Adjusted EBITDA net of NCI, are non-GAAP financial measures and should be examined in connection with net income determined in accordance with GAAP as presented in the consolidated financial statements and notes thereto included in our filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended March 31, 2022 and our Report on Form 10-K for the year ended December 31, 2021. Please see the schedule of Supplemental Non-GAAP Disclosures - 2022 Revised Operating Results Forecast, as included herein for additional information and a reconciliation to the financial forecasts as computed in accordance with GAAP.  

In addition, the 2022 revised forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as, pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain marketable securities and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impairments of goodwill and long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from included assumptions. It is also subject to certain conditions including those as set forth below in General Information,

 

 

Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures, including the likelihood that our future operations and financial results may continue to be materially impacted by developments related to COVID-19 and labor pressures caused by the nationwide shortage of nurses and other clinical staff and support personnel, as discussed herein.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2021 were approximately $12.6 billion. In 2022, UHS was again recognized as one of the World’s Most Admired Companies by Fortune; ranked #297 on the Fortune 500; and in 2021, ranked #307 on Forbes’ list of America’s Largest Public Companies.

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.  Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has over 89,000 employees and through its subsidiaries operates 28 acute care hospitals, 336 behavioral health facilities, 41 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 U.S. states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).  For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations.  Numerous factors, including those disclosed herein, those related to the anticipated impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 2-Forward Looking Statements and Risk Factors in our Form 10-Q for the quarter ended March 31, 2022 and in Item 1A-Risk Factors and in Item 7-Forward-Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2021), may cause the results to differ materially from those anticipated in the forward-looking statements.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof.  We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  Many of the factors that could affect our future results are beyond our control or ability to predict, including the impact of the COVID-19 pandemic. Our future operations and financial results will likely be materially impacted by developments related to COVID-19 including, but not limited to, the potential impact on future COVID-19 patient volumes resulting from new variants of the virus, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated at our hospitals and other healthcare facilities; measures we are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation and stimulus on the hospital industry and potential retrospective adjustment in future periods of CARES Act and other grant income revenues recorded as revenues in prior periods; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to our clinical staffing and shortages and disruptions related to supplies required for our employees and patients; potential increases to expenses and other costs related to staffing, supply chain, construction and medical equipment costs and other expenditures resulting from inflation; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in our markets resulting from the COVID-19

 

 

pandemic. We are not able to fully quantify the impact that these factors will have on our future financial results, but developments related to the COVID-19 pandemic could continue to materially affect our financial performance during 2022.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill and long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended March 31, 2022 and our Report on Form 10-K for the year ended December 31, 2021. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)


 

 

 

Universal Health Services, Inc.

Supplemental Non-GAAP Disclosures

2022 Revised Operating Results Forecast

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Forecast For The Year Ending December 31, 2022

 

 

 

 

 

 

 

 

 

% Net

 

 

 

 

 

 

% Net

 

 

 

 

 

Low

 

 

revenues

 

 

High

 

 

revenues

 

 

Net revenues (a)

 

 

$

13,235,000

 

 

 

 

 

 

$

13,371,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted net income attributable to UHS (a) (b)

$

701,705

 

 

 

 

 

 

$

760,204

 

 

 

 

 

 

Depreciation and amortization

 

 

 

590,483

 

 

 

 

 

 

 

590,483

 

 

 

 

 

 

Interest expense

 

 

 

129,472

 

 

 

 

 

 

 

129,472

 

 

 

 

 

 

Other (income) expense, net

 

 

 

(5,210

)

 

 

 

 

 

 

(5,210

)

 

 

 

 

 

Provision for income taxes

 

 

 

218,261

 

 

 

 

 

 

 

236,593

 

 

 

 

 

 

Adjusted EBITDA net of NCI (a) (c)

$

1,634,711

 

 

 

12.4

%

 

$

1,711,542

 

 

 

12.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted net income attributable to UHS, per diluted share (a) (b)

$

9.60

 

 

 

 

 

 

$

10.40

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing diluted earnings per share

 

72,972

 

 

 

 

 

 

 

72,972

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material unfavorable effect on our operations and financial results. The extent to which the COVID-19 pandemic and measures taken in response thereto impact our business, results of operations and financial condition will depend on numerous factors and future developments, most of which are beyond our control or ability to predict. The nationwide shortage of nurses and other clinical staff and support personnel has also been a significant operating issue facing us and other healthcare providers. The ultimate impact of the COVID-19 pandemic and the healthcare staffing shortage is highly uncertain and subject to change. We are not able to fully quantify the impact that these factors will have on our future financial results, but expect developments related to the COVID-19 pandemic and the staffing shortage to materially affect our financial performance in 2022 and may cause our 2022 actual operating results to differ materially from our 2022 operating results forecast.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(b) Adjusted net income attributable to UHS/per diluted share are non-GAAP financial measures.  The 2022 forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities, and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impairment of goodwill and long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. It is also subject to certain conditions including those as set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(c) Adjusted EBITDA net of NCI is a non-GAAP financial measure.  To obtain a complete understanding of our financial performance, Adjusted EBITDA net of NCI should be examined in connection with net income determined in accordance with GAAP as presented in the consolidated financial statements and notes thereto in our filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended March 31, 2022 and our Report on Form 10-K for the year ended December 31, 2021.

 

 

 EX-101.SCH 3 uhs-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 uhs-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 uhs-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jun. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2022
Entity Registrant Name UNIVERSAL HEALTH SERVICES, INC.
Entity Central Index Key 0000352915
Entity Emerging Growth Company false
Entity File Number 1-10765
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 23-2077891
Entity Address, Address Line One UNIVERSAL CORPORATE CENTER
Entity Address, Address Line Two 367 SOUTH GULPH ROAD
Entity Address, City or Town KING OF PRUSSIA
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19406
City Area Code 610
Local Phone Number 768-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Class B Common Stock
Trading Symbol UHS
Security Exchange Name NYSE
XML 7 uhs-8k_20220630_htm.xml IDEA: XBRL DOCUMENT 0000352915 2022-06-30 2022-06-30 false 0000352915 8-K 2022-06-30 UNIVERSAL HEALTH SERVICES, INC. DE 1-10765 23-2077891 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406 610 768-3300 false false false false Class B Common Stock UHS NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports uhs-8k_20220630.htm uhs-20220630.xsd uhs-20220630_lab.xml uhs-20220630_pre.xml uhs-ex991_6.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uhs-8k_20220630.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "uhs-8k_20220630.htm" ] }, "labelLink": { "local": [ "uhs-20220630_lab.xml" ] }, "presentationLink": { "local": [ "uhs-20220630_pre.xml" ] }, "schema": { "local": [ "uhs-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uhs", "nsuri": "http://www.uhsinc.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20220630.htm", "contextRef": "C_0000352915_20220630_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20220630.htm", "contextRef": "C_0000352915_20220630_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-22-024881-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-024881-xbrl.zip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end